Precision BioSciences DTIL 深 滬
已收盤 02-06 16:00:00 美东时间
3.80
+0.230
+6.44%
華盛通- 最 高3.825
- 今 開3.61
- 成交量 9.16万股
- 最 低 3.58
- 昨 收 3.57
- 總市值 9147.27万
- 52周最高 8.82
- 市盈率 靜 3.65
- 換手率 0.38%
- 52周最低 3.53
- 委 比 90.91%
- 總股本 2407.18万
- 歷史最高 710.10
- 量 比 0.52
- 振 幅 6.86%
- 歷史最低 3.53
- 每 手 1
- 風險率 0.77%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Precision BioSciences Highlights 2026 Gene Editing Priorities
Precision BioSciences ( ($DTIL) ) has issued an announcement. On January 12, 20...
01-14 05:28
Precision Biosciences Advances Gene Therapy Pipeline With Ongoing Phase 1/2a ELIMINATE‑B Trial For PBGENE‑HBV And Anticipated Q1 2026 IND Clearance For PBGENE‑DMD; Data Updates Expected Throughout 2026
Phase 1/2a ELIMINATE-B trial for PBGENE-HBV ongoing across multiple dosing cohorts; Data updates expected at medical conferences in 2026PBGENE-DMD expecting IND clearance in Q1 2026 for Phase 1/2 FUNCTION-DMD study with
01-12 20:19
H.C. Wainwright Keeps Their Buy Rating on Precision BioSciences (DTIL)
H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Precision B...
2025-11-21 23:45
Precision BioSciences to Present Gene Editing Therapy for Chronic Hepatitis B at Hep-DART 2025
Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today
2025-11-19 20:03
Precision BioSciences Announces $70M Stock Offering
Precision BioSciences ( ($DTIL) ) just unveiled an announcement. On November 10...
2025-11-12 22:28
Precision BioSciences launches $75M stock and warrant offering
Precision BioSciences (DTIL) on Monday reported an underwritten offering of about 10.8 million shares of its common stock, along with warrants to buy up to 5.4 million additional shares, at a combined...
2025-11-11 15:41
Precision BioSciences Unveils Promising ELIMINATE-B Trial Results
Precision BioSciences ( ($DTIL) ) has provided an update. On November 10, 2025,...
2025-11-11 06:57
Precision BioSciences' First-in-Class Gene Editing Therapy PBGENE-HBV Shows Dose-Dependent Antiviral Response And Evidence Of Viral DNA Editing In Phase 1 ELIMINATE-B Study, Offering Potential Path Toward Chronic Hepatitis B Cure; To Host Conference Call Tomorrow, November 11th At 8:00 am ET
PBGENE-HBV, the first gene editing therapy designed to treat chronic Hepatitis B by directly targeting HBV cccDNA and integrated HBV DNA, showcased as the final oral presentation in the late-breaking AASLD session at
2025-11-11 06:25
Precision BioSciences shares are trading lower after the company reported worse-than-expected Q3 financial results.
Precision BioSciences shares are trading lower after the company reported worse...
2025-11-04 00:51
Precision BioSciences Q3 EPS $(1.84) Misses $(1.34) Estimate, Sales $13.000K Miss $5.400M Estimate
Precision BioSciences (NASDAQ:DTIL) reported quarterly losses of $(1.84) per share which missed the analyst consensus estimate of $(1.34) by 37.31 percent. This is a 18.22 percent increase over losses of $(2.25) per
2025-11-03 20:01
